Aridis pharmaceuticals, inc. (ARDS)
Balance Sheet / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Dec'17
Assets
Current assets:
Cash and cash equivalents

16,324

20,897

17,330

8,519

16,311

24,237

34,077

13,470

25,096

Accounts receivable

-

-

-

1,000

0

1,660

800

-

-

Other receivables

261

413

-

-

-

438

-

-

-

Contract costs

1,543

1,537

-

-

-

-

-

-

-

Other receivables

-

-

10,601

1,448

2,142

-

-

-

-

Prepaid expenses

1,848

2,990

3,159

2,390

2,058

2,012

1,405

960

244

Total current assets

19,976

25,837

31,090

13,357

20,511

28,347

36,282

14,430

25,340

Property and equipment, net

923

1,006

1,075

1,135

1,190

1,271

1,231

1,280

750

Intangible assets, net

31

32

34

35

36

38

39

41

43

Equity method investment

-

9

50

332

518

960

980

-

-

Contract costs

520

526

-

-

-

-

-

-

-

Other assets

557

557

2,118

1,015

995

995

41

345

345

Total assets

22,007

27,967

34,367

15,874

23,250

31,611

38,573

16,096

26,478

Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable

1,967

1,755

3,125

1,544

2,716

2,331

1,760

610

933

Accrued liabilities

2,815

2,974

2,863

3,468

1,825

2,944

4,890

2,330

2,121

Deferred revenue, current

14,661

14,602

2,538

-

-

22

553

775

120

Dividends payable

-

-

-

-

-

-

-

1,352

-

Total current liabilities

19,443

19,331

8,526

5,012

4,541

5,297

7,203

5,067

3,174

Deferred revenue

4,941

5,000

17,064

-

-

-

-

-

-

Warrant liability

-

-

-

-

-

-

-

8,847

11,868

Total liabilities

24,384

24,331

25,590

5,012

4,541

5,297

7,203

13,914

15,042

Total convertible preferred stock

-

-

-

-

-

-

-

74,202

74,202

Commitments and contingencies (Note 11)

-

-

-

-

-

-

0

0

-

Stockholders' equity (deficit):
Common stock (par value $0.0001; 100,000,000 shares authorized; shares issued and outstanding: 8,923,374 and 8,918,461 as of March 31, 2020 and December 31, 2019, respectively)

1

1

1

1

1

1

1

-

-

Additional paid-in capital

104,895

104,404

103,897

98,395

97,859

97,401

97,018

-14,285

-15,140

Accumulated deficit

-107,273

-100,769

-95,121

-87,534

-79,151

-71,088

-65,649

-57,735

-47,626

Total stockholders' equity (deficit)

-2,377

3,636

8,777

10,862

18,709

26,314

31,370

-72,020

-62,766

Total liabilities and stockholders' equity (deficit)

22,007

27,967

34,367

15,874

23,250

31,611

38,573

16,096

26,478

Series A Convertible Preferred Stock
Total convertible preferred stock

-

-

-

-

-

-

-

-

74,202

Series A convertible preferred stock (par value $0.0001; 60,000,000 shares authorized; zero shares issued and outstanding as of September 30, 2019 and December 31, 2018, respectively)

-

-

0

0

0

-

-

-

-